欢迎来到天天文库
浏览记录
ID:53727167
大小:281.72 KB
页数:4页
时间:2020-04-20
《尼妥珠单抗联合顺铂同步放化疗治疗中晚期鼻咽癌的近期疗效.pdf》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、一50一肿瘤药学2014年2月第4卷第1期Anti—tumorPharmacy,February2014,Vo1.4,No.1尼妥珠单抗联合111~.$13同步放化疗治疗中晚期鼻咽癌的近期疗效卢辉,倪福春,刘丽英,王倩,司晓燕(郑州市第一人民医院肿瘤血液科,河南郑州,450001)摘要:目的探讨尼妥珠单抗联合顺铂同步放化疗治疗中晚期鼻咽癌的临床效果。方法随机抽取我院2009—2012年收治的54例中晚期鼻咽癌患者,根据治疗方法的不同分为对照组和观察组,每组27例,对照组采用顺铂同步放化疗治疗,观察组在顺铂同步放化疗治疗的基础
2、上加以尼妥珠单抗联合治疗,治疗后观察和评价两组患者的治疗效果。结果对照组和观察组的治疗总有效率分别为74.1%和96.3%,观察组明显高于对照组,差异具有统计学意义(P<0.05)。观察组治疗过程中各种不良反应如心电图异常、消化道反应、脱发、发热、中性粒细胞减少、红细胞减少、血小板减少应的发生率均显著低于对照组(P<0.05)。结论尼妥珠单抗联合顺铂同步放化疗治疗局部晚期鼻咽癌的疗效显著,优于单纯同步放化疗,且毒副作用更少,安全性高,值得I临床推广与应用。关键词:尼妥珠单抗;同步放化疗;中晚期鼻咽癌;临床效果中图分类号:R7
3、39.6文献标识码:A文章编号:2095—1264(2014)01—0050—04doi:10.3969~.issn.2095—1264.2014.010NimotuzumabConcurrentRadiotherapyandCisplatinChemotherapyinAdvancedNas0pharyngealCarcinomaLUHui,NIFuchun,LIULiying,WANGQian,SIXiaoyan(ZhengzhouFirstPeople"sHospi~lDepartmentofHematologyTum
4、or,Zhengzhou,Henan,450001,China)Abstract:ObjectiveToinvestigatetheeffectofnimotuzumabwithconcurrentcisplatinradiochemotherapyonad—vancednasopharyngealcarcinoma.MethodsAtotalof54patientswithadvancednasopharyngealcarcinomainourhospitalbetween2009and2012wererandomlydi
5、videdintocontrolgroupandobserv~iongroup,andeachgrouphad27cases.Thecontrolgroupweretreatedwithconcurrentcisplatinradiochemotherapy,andtheobservationgroupweretreatedwithnimotuzumahcombinedwithconcurrentcisplatinradiochemotherapy.Aftertreatment.thetherapeuticeffectoft
6、wogroupswereobservedandevaluated.ResultsThetotalefectiveratewas74.1%inthecontrolgroupand96_3%intheobserva-tiongroup,whichwassignificantlyhigherinobservationgroup.Thediferencewasstatisticallysignificant<0.05).Du卜ingthetreatmentgroup,theincidenceofadversereactionssuc
7、hasECGabnormalities,gastrointestinalreactions,hairloss,fever,nentropenia,redbloodcells,thrombocytopeniawassignificantlylowerinobservationgroupthaninthecontrolgroup<0.05).ConclusionNimotuzumabcombinedwithconeulTentcisplatinchemoradiotherapyhadsignificantlybe~erefect
8、onthelocallyadvancednasopharyngealcarcinomathanconcurrentchemoradiotherapy,andhadfewersideefects.Itwassafeandworthyofclinicalapplication.Keywords
此文档下载收益归作者所有